SuStaIn was originally applied to structural MRIs in Alzheimer’s disease whilst more recent work includes identifying distinct patterns of tau and amyloid accumulation in Alzheimer’s disease using PET data.22,23 The clinical, anatomical and pathological heterogeneity of CBS makes it ideally suited to modelling using SuStaIn. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.